ALX ONCOLOGY HOLDINGS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $0 | $0 |
| Research and development | $77.0M | $116.4M | $141.8M | $98.4M | $60.2M |
| Operating expenses | $104.0M | $142.5M | $170.3M | $127.4M | $83.6M |
| Operating income | -$104.0M | -$142.5M | -$170.3M | -$127.4M | -$83.6M |
| Interest expense | $1.6M | $1.7M | $1.6M | $238,000 | $13,000 |
| Pretax income | -$101.7M | -$134.8M | -$160.8M | -$123.4M | -$83.5M |
| Income tax expense | $0 | $0 | $0 | $64,000 | -$21,000 |
| Net income | -$101.7M | -$134.8M | -$160.8M | -$123.5M | -$83.5M |
| Balance Sheet | |||||
| Cash and equivalents | $16.4M | $17.6M | $22.4M | $48.8M | $363.7M |
| Current assets | $50.7M | $134.4M | $188.7M | $271.0M | $367.0M |
| Total assets | $59.0M | $147.8M | $242.6M | $306.5M | $380.2M |
| Current liabilities | $24.6M | $18.5M | $36.0M | $28.3M | $15.3M |
| Total liabilities | $33.1M | $34.2M | $52.8M | $43.0M | $17.1M |
| Stockholders' equity | $26.0M | $113.6M | $189.7M | $263.5M | $363.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$84.1M | -$121.9M | -$130.4M | -$89.2M | -$68.1M |
| Depreciation and amortization | $706,000 | $872,000 | $836,000 | $342,000 | $51,000 |
| Stock-based compensation | $12.6M | $27.1M | $26.3M | $23.8M | $13.9M |
| Capital expenditure | $212,000 | $447,000 | $1.3M | $1.4M | $666,000 |
| Free cash flow | -$84.4M | -$122.4M | -$131.6M | -$90.7M | -$68.8M |
| Impairments | $3.2M | $0 | $0 | $0 | $0 |
Shares outstanding 134.6M · Free float 71.8%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.